Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy-Reference-Cited by-同舟云学术

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy

Published:2022-01-01 Issue:1 Volume:29 Page:24-37
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Furuhashi Masato¹,Sakuma Ichiro²,Morimoto Takeshi³,Higashiura Yukimura¹,Sakai Akiko¹,Matsumoto Megumi¹,Sakuma Mio³,Shimabukuro Michio⁴,Nomiyama Takashi⁵,Arasaki Osamu⁶,Node Koichi⁷,Ueda Shinichiro⁸

Affiliation:

1. Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine

2. Caress Sapporo Hokko Memorial Clinic

3. Department of Clinical Epidemiology, Hyogo College of Medicine

4. Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University

5. Department of Diabetes, Metabolism and Endocrinology, International University of Health and Welfare Ichikawa Hospital

6. Department of Cardiology, Tomishiro Central Hospital

7. Department of Cardiovascular Medicine, Saga University

8. Department of Pharmacology and Therapeutics, University of the Ryukyus

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/29/1/29_58396/_pdf

Reference59 articles.

1. 1) Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2018; 41: 2669-2701

2. 2) Fisman EZ, Tenenbaum A: Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol, 2015; 14: 129

3. 3) Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S, Kadowaki T: A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun, 2013; 434: 191-196

4. 4) Watanabe YS, Yasuda Y, Kojima Y, Okada S, Motoyama T, Takahashi R, Oka M: Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions. J Enzyme Inhib Med Chem, 2015; 30: 981-988

5. 5) Kaku K: Effects of anagliptin on serum lipids in Japanese patients with type 2 diabetes - a pooled analysis of long-term therapy with anagliptin. Jpn Pharmacol Ther, 2012; 40: 771-784

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review);International Journal of Molecular Medicine;2024-05-10

2. Insight into the role of PCSK9 in glucose metabolism;Clinica Chimica Acta;2023-07

3. Evaluation of Terpenoids as Dipeptidyl Peptidase 4 Lead Molecules: Molecular Docking and Dynamics Simulation Study;Biointerface Research in Applied Chemistry;2022-10-31

4. High fatty liver index is an independent predictor of ischemic heart disease during a 10‐year period in a Japanese population;Hepatology Research;2022-06

5. The Reason is Still Unclear;Journal of Atherosclerosis and Thrombosis;2022-01-01